Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-16
2010-11-23
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S262200
Reexamination Certificate
active
07838544
ABSTRACT:
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.
REFERENCES:
patent: 3666860 (1972-05-01), Berkelhammer et al.
patent: 3770748 (1973-11-01), Borck et al.
patent: 3933829 (1976-01-01), Archibald et al.
patent: 4001422 (1977-01-01), Danilewicz et al.
patent: 4013445 (1977-03-01), Bellus et al.
patent: 4076819 (1978-02-01), Maffrand
patent: 4439606 (1984-03-01), Du et al.
patent: 5076961 (1991-12-01), Nakamura et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5614534 (1997-03-01), Binet et al.
patent: 5633247 (1997-05-01), Baldwin et al.
patent: 5668138 (1997-09-01), Baziard-Mouysset et al.
patent: 5852029 (1998-12-01), Fisher et al.
patent: 5981754 (1999-11-01), Badone et al.
patent: 6547958 (2003-04-01), Elomari et al.
patent: 2003/0229119 (2003-12-01), Kym et al.
patent: 2005/0020645 (2005-01-01), Ohta et al.
patent: 2005/0080078 (2005-04-01), Aquila et al.
patent: 2005/0282858 (2005-12-01), Yao et al.
patent: 2005/0288317 (2005-12-01), Yao et al.
patent: 2005/0288329 (2005-12-01), Yao et al.
patent: 2005/0288338 (2005-12-01), Yao et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2006/0009471 (2006-01-01), Yao et al.
patent: 2006/0009491 (2006-01-01), Yao et al.
patent: 2006/0019977 (2006-01-01), Habashita et al.
patent: 2006/0106045 (2006-05-01), Hughes et al.
patent: 2006/0116382 (2006-06-01), Yao et al.
patent: 2006/0122197 (2006-06-01), Yao et al.
patent: 2006/0122210 (2006-06-01), Yao et al.
patent: 2006/0149070 (2006-07-01), Rohde et al.
patent: 2006/0199816 (2006-09-01), Gillespie et al.
patent: 2007/0066584 (2007-03-01), Yao et al.
patent: 2007/0129345 (2007-06-01), Zhuo et al.
patent: 2007/0179142 (2007-08-01), Yao et al.
patent: 2007/0197506 (2007-08-01), Yao et al.
patent: 2007/0197530 (2007-08-01), Li et al.
patent: 2007/0208001 (2007-09-01), Zhuo et al.
patent: 2007/0213311 (2007-09-01), Li et al.
patent: 2007/0275990 (2007-11-01), Ohmoto et al.
patent: 2007/0293529 (2007-12-01), Li et al.
patent: 2008/0255154 (2008-10-01), Yao et al.
patent: 2008/0318991 (2008-12-01), Yao et al.
patent: 2623567 (1976-12-01), None
patent: 136963 (1979-08-01), None
patent: 1683797 (2006-07-01), None
patent: 4334357 (1992-11-01), None
patent: WO 03037847 (2003-05-01), None
patent: WO 03/053915 (2003-07-01), None
patent: WO 03/065983 (2003-08-01), None
patent: WO 2004/056745 (2004-07-01), None
patent: WO 2004/056789 (2004-07-01), None
patent: WO 2004/058253 (2004-07-01), None
patent: WO 2004065351 (2004-08-01), None
patent: WO 2004/082687 (2004-09-01), None
patent: WO 2004089470 (2004-10-01), None
patent: WO 2004089896 (2004-10-01), None
patent: WO 2004/106294 (2004-12-01), None
patent: WO 2005/044192 (2005-05-01), None
patent: WO 2005047286 (2005-05-01), None
patent: WO 2005060963 (2005-07-01), None
patent: WO 2005063745 (2005-07-01), None
patent: WO 2005/087764 (2005-09-01), None
patent: WO 2005/095350 (2005-10-01), None
patent: WO 2005/110992 (2005-11-01), None
patent: WO 2005108359 (2005-11-01), None
patent: WO 2006002350 (2006-01-01), None
patent: WO 2006/012227 (2006-02-01), None
patent: WO 2006/020598 (2006-02-01), None
patent: WO 2006012226 (2006-02-01), None
patent: WO 2006/047196 (2006-05-01), None
patent: WO 2006/080533 (2006-08-01), None
patent: WO 2006/130986 (2006-12-01), None
Alberts et al. Endocrinology (2003) 144: 4755-4762.
Albiston et al. (1994) Mol. Cell. Endocrin. 105: R11-R17.
Barf et al. (2002) J. Med. Chem. 45: 3813-3815.
Bellows et al. (1998) Bone 23: 119-125.
Ben el al., “Synthesis of Opticaly Active α-Amino Esters via Dynamic Kinetic Resolution: A Mechanistic Study,”J. Org. Chem.64: 7700-7706 (1999).
Bhargava et al., (2001), Endo 142: 1587-1594.
Billaudel and Sutter (1979) Horm. Metab. Res. 11: 555-560.
Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Blum, et al., (2003) Prog. Nucl. Acid Res. Mol. Biol. 75:173-216.
Bujalska et al. (1997) Lancet 349: 1210-1213.
Buzas, A. et al.,Chimica Therapeutica, The European Journal of Medicinal Chemistry,7 (5), pp. 361-426, 1972.
Canalis (1996) J. Clin. Endocrinol. Metab. 81: 3441-3447.
Conn, (1955), J. Lab. Clin. Med. 45: 6-17.
Cooper et al. (2000) Bone 27: 375-381.
Database CAPLUS on STN (Columbus, OH, USA) No. 108:131815, Preparation and testing of 17-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones as phosphodiesterase and bloodplatelet aggregation inhibitors', abstract, Meanwell, et al. (1988) see RN 113288-90-7.
Database CAPLUS on STN (Columbus, OH, USA) No. 118:255342, {re[artopm pf M-heterpcuc:u;carbpmu;a,omp acids and analogs as prolylendopeptidase inhibotors' abstract, Hosoda et al. (1993) see RN 147635-61-8.
Database CAPLUS on STN (Columbus, OH, USA) No. 126:317635, “Alpha-amino acids derived from ornithine as building blocks for peptide synthesis” abstract, Gescrinier et al. j. Pep. Res. 49(2):183-189 (1997).
Database CAPLUS on STN (Columbus, OH, USA) No. 143:78479, “Preparation of amino acid derivatives as novel M3 muscarinic acetylcholine receptor antagonists” abstract, Busch et al. (2005), see RN 902149-23-9 and 854750-92-8.
Davani et al. (2000) J. Biol. Chem. 275: 34841-34844.
Draper et al. (2003) Nat. Genet. 34: 434-439.
Edwards et al. (1988) Lancet 2: 986-989.
Engeli, et al., (2004) Obes. Res. 12: 9-17.
Funder et al. (1988), Science 242: 583-585.
Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991.
Gu et al., “Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11 β-HSDI : Novel therapeutic agents for the treatment of metabolic syndrome,”Bioorg. Med Chem. Lett.,15:5266-5269 (2005).
Hermanowski-Vosatka et al. (2005) J. Exp. Med. 202: 517-527.
Irikura, Tsutomu and Kasuga, Kazunori, “New Antiulcer Agents. Syntheases and biological Activities of 1-Acyl-2, -3-, and -4-Substituted Benzamidopiperidine”,Journal of Medicinal Chemistry,14 (4), pp. 357-361, 1971.
Jausons-Loffreda et al. J. Biolumin and Chemilumin, 9:217-221 (1994).
Journal of Pharmaceutical Science, 66, 2 (1977).
Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929.
Kurukulasuriya , et al., (2003) Curr. Med. Chem. 10: 123-53.
Leonardi et al., “Synthesis, Pharmacological Evaluation, and Structure—Activity Relationship and Quantitative Structure—Activity Relationship Studies on Novel Derivatives of 2,4-Diamitto-6,7-dimethoxyquinazoline α1-Adrenoceptor Antagonists,”J. Med. Chem.,42:427-437 (1999).
Lindsay et al. (2003) J. Clin. Endocrinol. Metab. 88: 2738-2744.
Livingstone et al. (2000) Endocrinology 131: 560-563.
Low et al. (1994) J. Mol. Endocrin. 13: 167-174.
Lupien et al. (1998) Nat. Neurosci. 1: 69-73.
Mallams et al., “Inhibitors of Farnesyl Protein Transferase, 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine,”J. Med. Chem.,41:877-893 (1998).
Masuzaki et al. (2001) Science 294: 2166-2170.
Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90.
Masuzaki, et al., (2003) Curr. Drug Targets Immune Endocr. Metabol. Disord. 3: 255-62.
Matsumoto et al., “Direkte Aminolyse von nicht aktivierten Estern bei hohm Druck,”Angew. Chem.98: 569-570 (1986).
Matsuzawa et al. (1999) Ann. N.Y. Acad. Sci. 892: 146-154.
McEwen and Sapolsky (1995) Curr. Opin. Neurobiol. 5: 205-216.
Miller and Chrousos (2001) Endocrinology and Metabolism, eds. Felig and Frohman (McGraw-Hill, New York), 4th Ed.: 387-524.
Moeller et al., “Anodic Amide Oxidations in the Presence of Electron-Rich Phenyl Rings: Evidence for an Intramolecular Electron-Transfer Mechanism,”J. Org. Chem.,56:1058-1067 (1991).
Morton et at. (
Li Yun-Long
Yao Wenqing
Zhuo Jincong
Bianchi Kristin
Fish & Richardson P.C.
Incyte Corporation
Saeed Kamal A
LandOfFree
Heterocyclic inhibitors of 11-β hydroxyl steroid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of 11-β hydroxyl steroid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of 11-β hydroxyl steroid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195179